Reimbursement and Access 2019

Reimbursement and Access 2019 August 13-14, 2019 | DoubleTree by Hilton Center City | Philadelphia, PA www.cbinet.com/Reimbursement For all companies within the life sciences arena, staying on the pulse of emerging trends, ensuring favorable reimbursement and justifying product prices are core pillars of overall product success. Whether your organization is pre-commercial or managing multiple products, CBI’s Reimbursement and Access conference convenes stakeholders from across the life sciences community to provide insight into real-time policy briefings, impactful managed markets trends and strategies to ensure product access. Drug Channels readers can register using discount code QEF679 to receive $500 off* the standard … Continue reading Reimbursement and Access 2019

A New Starting Point for Patient Support: Technology-Driven Hub Services

Today’s guest post comes from Erica Conroy, VP of Specialty at CoverMyMeds and Bill Nolan, VP/GM of Access and Adherence at RxCrossroads by McKesson. Erica and Bill discuss the challenges that specialty pharmacy patients encounter when accessing and utilizing hub services. They also present evidence showing that how hub services positively affect patient outcomes. To learn more, download CoverMyMeds’ whitepaper: Revolutionizing Patient Access and Support for Specialty Therapies: Multiple Sclerosis. Read on for their insights. Read more » Copyright © 2006-2019 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed … Continue reading A New Starting Point for Patient Support: Technology-Driven Hub Services

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway

Activation of tumor suppressors for the treatment of human cancer has been a long sought, yet elusive, strategy. PTEN is a critical tumor suppressive phosphatase that is active in its dimer configuration at the plasma membrane. Polyubiquitination by the ubiquitin E3 ligase WWP1 (WW domain–containing ubiquitin E3 ligase 1) suppressed the dimerization, membrane recruitment, and function of PTEN. Either genetic ablation or pharmacological inhibition of WWP1 triggered PTEN reactivation and unleashed tumor suppressive activity. WWP1 appears to be a direct MYC (MYC proto-oncogene) target gene and was critical for MYC-driven tumorigenesis. We identified indole-3-carbinol, a compound found in cruciferous vegetables, … Continue reading Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway

Erratum for the Report “Conformationally supple glucose monomers enable synthesis of the smallest cyclodextrins” by D. Ikuta, Y. Hirata, S. Wakamori, H. Shimada, Y. Tomabechi, Y. Kawasaki, K. Ikeuchi, T. Hagimori, S. Matsumoto, H. Yamada

Powered by WPeMatico Continue reading Erratum for the Report “Conformationally supple glucose monomers enable synthesis of the smallest cyclodextrins” by D. Ikuta, Y. Hirata, S. Wakamori, H. Shimada, Y. Tomabechi, Y. Kawasaki, K. Ikeuchi, T. Hagimori, S. Matsumoto, H. Yamada

340B Health Gets It Wrong … Again

This week, Drug Channels published our annual update on the growth of the 340B Drug Pricing Program. See 340B Program Purchases Reach $24.3 Billion—7%+ of the Pharma Market—As Hospitals’ Charity Care Flatlines. Right on cue, 340B Health, which lobbies for hospitals that participate in the 340B program, immediately issued its annual rebuttal of the Health Resources and Services Administration (HRSA) data that we used. 340B Health was particularly distressed that our analyses “focused on 340B sales instead of discounts.” Below, you will see that when the program is measured using 340B Health’s suggested approach, it accounted for 9% to 11% … Continue reading 340B Health Gets It Wrong … Again

EXCLUSIVE: 340B Program Purchases Reach $24.3 Billion—7%+ of the Pharma Market—As Hospitals’ Charity Care Flatlines

The 340B Drug Pricing Program continues to expand at double-digit rates. According to our government contacts, discounted 340B purchases hit a record $24.3 billion in 2018. That figure is an astonishing 26% higher than its 2017 counterpart. What’s more, we have found that since 2014, purchases under the program have grown at an average rate of 28% per year. By comparison, manufacturers’ net drug revenues have grown at an average rate of below 5% over the same period. Consequently, the 340B program has grown to account for at least 7% to 8% of the total U.S. drug market. Nearly all … Continue reading EXCLUSIVE: 340B Program Purchases Reach $24.3 Billion—7%+ of the Pharma Market—As Hospitals’ Charity Care Flatlines

CBI’s Strategic Medicare Contracting Forum for Bio/Pharmaceutical Manufacturers

CBI’s Strategic Medicare Contracting Forum for Bio/Pharmaceutical Manufacturers June 19-20, 2019 | Alexandria, VA www.cbinet.com/Medicare CBI’s Strategic Medicare Contracting Forum for Bio/Pharma Manufacturers provides a real-time analysis of newly proposed regulations, including the proposal to eliminate rebates, the use of step therapy under Medicare Part B, changes to coverage gap, influence of the International Pricing Index and much more. Exclusive Offer for Drug Channels Readers: Register Now and SAVE $400* using promo code MED400. Taking place June 19-20 in Alexandria, VA, we invite you to convene with fellow stakeholders to receive an in-depth look into legislative and regulatory changes to Medicare … Continue reading CBI’s Strategic Medicare Contracting Forum for Bio/Pharmaceutical Manufacturers